AWS
GTBP icon

Atria Wealth Solutions’s GT Biopharma GTBP Stock Holding History

Atria Wealth Solutions’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,291
Closed -$25.2K – 2003
2023
Q4 		$25.2K Buy
3,291
+334
+11% +$2.44K ﹤0.01% 1906
2023
Q3 		$21.4K Buy
2,957
+666
+29% +$5.5K ﹤0.01% 1841
2023
Q2 		$21.4K Hold
2,291
– – ﹤0.01% 1843
2023
Q1 		$37.8K Hold
2,291
– – ﹤0.01% 1818
2022
Q4 		$60.9K Hold
2,291
– – ﹤0.01% 1727
2022
Q3 		$121K Hold
2,291
– – ﹤0.01% 1616
2022
Q2 		$205K Buy
2,291
+1,958
+588% +$148K ﹤0.01% 1446
2022
Q1 		$29K Buy
+333
New +$29.4K ﹤0.01% 1713

Other funds holding GTBP

Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Atria Wealth Solutions's GTBP Position: Q1 2024 in Review

Atria Wealth Solutions sold out of GT Biopharma (GTBP) in Q1 2024, closing a stake of 3,291 shares — an estimated $25.2K sold.

Atria Wealth Solutions first reported a position in GTBP in Q1 2022 and held it in 8 quarters. The position peaked at $205K in Q2 2022. 17 funds tracked by Wall St. Rank hold GTBP as of Q1 2024.

  • Atria Wealth Solutions reported no remaining GT Biopharma position as of Q1 2024 after selling out during the quarter.
  • Atria Wealth Solutions sold 3,291 GT Biopharma shares in Q1 2024, an estimated $25.2K.
  • Atria Wealth Solutions first reported a position in GT Biopharma in Q1 2022 and held it in 8 quarters.
  • Atria Wealth Solutions's GT Biopharma position peaked at $205K in Q2 2022.
  • 17 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2024.

Based on Atria Wealth Solutions's 13F filing for Q1 2024, filed 13 May 2024.